You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
The companies gained FDA approval for the Liaison QuantiFeron-TB Plus Test, an automated workflow and assay for latent tuberculosis detection.
Called Ion, the system combines low magnification, high-resolution imaging with a proprietary image analysis algorithm for rapid pathogen detection.
The collaboration will align diagnostic placement with treatment capacity for tuberculosis and HIV, among other diseases.
As a result of its collaboration with Quest Diagnostics, Oxford Immunotec is experiencing a surge in orders from physician offices for its interferon gamma release assay TB kits.
The firm is investing in commercial resources and research and development to capitalize on continued expansion in the global tuberculosis market, according to its CEO.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The firm said that it ended a distributor agreement that it had inked in 2013 with Fosun Long March Medical Science and Shanghai Xin Chang Medical Device.